CytomX Therapeutics (CTMX) Barclays 27th Annual Global Healthcare Conference summary

Platform and partnerships

• Probody platform enables tumor-specific delivery of therapeutics, enhancing safety and efficacy.

• Multiple partnerships with major pharma companies focus on T-cell engagers.

• Strong financial position with $101 million cash, providing runway into Q2 2026.

• Integrated R&D team of 70 employees supports clinical pipeline.

Clinical pipeline progress

• Two main clinical programs: CX-2051 (EpCAM-targeted ADC) and CX-801 (Probody interferon alfa-2b).

• Both programs are on track for initial phase I readouts in 2025.

• CX-2051 is in phase I dose escalation for advanced colorectal cancer, with initial data expected in the first half of 2024.

• CX-801 is in phase I for advanced melanoma, with translational biomarker data expected in the second half of 2024.

• Plans to initiate CX-801 combination with Keytruda in the second half of 2024.

Scientific and clinical rationale

• Probody platform leverages tumor-specific protease activity to activate masked therapeutics.

• CX-2051 aims to overcome historical toxicity barriers of EpCAM-targeted therapies by systemic delivery.

• Preclinical data show CX-2051 has a broad therapeutic window and activity in irinotecan-resistant models.

• CX-801 designed to harness interferon alpha’s immune activation while minimizing systemic toxicity.